Organization | Netherlands Institute for Pigment Disorders

Netherlands Institute for Pigment Disorders Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Amsterdam Netherlands (1994)

Organization Overview

First Clinical Trial

2009

NCT01085279

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Netherlands Institute for Pigment Disorders

Active Ingredients

Drugs in Phase 4 Trials (4)

articaine (Septocaine) (3 trials)

lidocaine (xylocaine) (3 trials)

prilocaine (citanest) (2 trials)

tetracaine (pontocaine) (1 trial)

Drugs in Phase 2 Trials (3)

hydroquinone (1 trial)

tretinoin (Retin-A) (1 trial)

triamcinolone (kenalog) (1 trial)

Drugs in Other Trials (1)

fluticasone (cutivate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cicatrix (Phase 4)

Pigmentation Disorders (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 8